12Gene therapy & the genomic future

FFrom explaining to treating

The arc of this chapter has been from explanation (which gene?) to prediction (how well will an implant work?). The natural next step is treatment: if a specific gene is broken, could it be repaired or replaced? The same sequencing revolution that made comprehensive diagnosis possible is what makes this question more than science fiction.[2011]

CThe horizon, in three stages

It helps to separate the timeline. Today, genetics delivers diagnosis, prognosis and counselling, and the cochlear implant treats the deafness. Emerging now is targeted gene replacement for selected single-gene defects. On the horizon lie broader gene and cell therapies and the regeneration of lost hair cells — mostly still experimental. Conflating these stages breeds either false hope or undue cynicism; holding them apart keeps expectations honest.

CWhy OTOF went first

It is no accident that otoferlin (OTOF) became the first inner-ear gene-therapy target. The biology is unusually favourable: it is a single gene with a clear loss-of-function mechanism; the hair cells survive (the defect is in synaptic transmitter release, not cell death), so there is a living cell to rescue; and the lesion is pre-neural, leaving the downstream pathway intact. Early-phase trials delivering a working OTOF gene to the inner ear have restored measurable hearing in children with OTOF-related deafness — the first real demonstration that inner-ear gene therapy can work.[2006]

CThe harder targets

OTOF is, in a sense, the easy case. Most deafness genes pose harder problems: many cause hair-cell loss (so there is no cell left to rescue, and regeneration — long sought, not yet achieved — would be needed); some are large genes that do not fit current delivery vectors; and the therapeutic window may have closed before diagnosis. Each is a research programme in its own right, and none is close to routine clinical use.

FTThe implant's place

None of this displaces the cochlear implant. For the overwhelming majority of genetic deafness, the implant remains today's treatment — effective, available, and improving. The realistic near-term role of genetics is the one this chapter has built: to diagnose, predict and counsel, and increasingly to offer gene therapy as a complement for the few genotypes where it works. Implant and gene therapy may come to coexist — the device restoring access now, the biology repairing the cause where it can.

FClosing the chapter

The chapter began with a puzzle — why identical audiograms give different implant results — and answered it with a principle: the gene reveals the site of the lesion, and the site predicts the outcome. Along the way, genetic testing moved from afterthought to front-line tool, the spiral-ganglion hypothesis turned genotype into prognosis, and the first gene therapies appeared on the horizon. Genetics has become part of the language of cochlear implantation — and, gene by gene, may yet become part of its cure.